This report presents the results of the first external quality assurance (EQA) scheme for B. pertussis antimicrobial susceptibility testing by ECDC as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) consortium.
This report presents the results of the first external quality assessment (EQA) scheme for Bordetella pertussis vaccine antigen expression, pertactin (PRN), pertussis toxin (PT) and filamentous haemagglutinin (FHA) by the European Centre for Disease Prevention and Control (ECDC) as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) activities.
At the start of European Immunization Week, the ECDC report “Poliomyelitis situation update” reveals that between 2012 and 2021, approximately 2.4 million children in the EU/EEA may have not received three doses of polio-containing vaccines on time. Additionally, the newly published ECDC “Measles Annual Epidemiological Report 2022” highlights the risks when having pockets of an under-vaccinated population or groups not immunised at all.
The European Region was declared polio-free in 2002. Since then, renewed circulation of wild poliovirus type 1 (WPV1) and outbreaks of circulating vaccine-derived poliovirus (cVDPV) has been observed globally.
This issue of the CDTR covers the period 16-22 April 2023 and includes updates on influenza, avian influenza, Marburg virus disease, COVID-19 and poliomyelitis.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 26 March - 1 April 2023 and includes updates on Iatrogenic botulism exposure in Türkiye, COVID-19, group A streptococcal infection, influenza, swine influenza. Marburg virus disease and poliomyelitis.
ECDC and WHO/Europe have issued a statement announcing that the European Region remains a long way from meeting its End Tuberculosis Strategy targets, despite having the tools to do so.